signumia
Data is being collected. The dashboard will appear when it is available.
SYMBOL
Data is being collected. The dashboard will appear when it is available.
WST

Close price

$340.41

Latest price

$350.02

Change vs close

+2.82%

Current price: $350.02

Market cap

24.73B

Pre-market and after-hours data may be partial or delayed depending on the source and licensing.

West Pharmaceutical Services, Inc.

WST

NYSE · Health Care · Medical/Dental Instruments

Company Profile

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 26 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.

Website

https://www.westpharma.com

Country

PA

Sector

Health Care

Industry

Medical/Dental Instruments

CIK

0000105770

Candlestick Chart

1D · Data source: loading

Loading candle data

Quarterly Performance Snapshot

Actual revenue and net income based on quarterly filings

Q2 Jul 2026

Quarterly Snapshot

Q2 Jul 2026

Mix

25.72B

Market cap

96.13%

24.73B

Expected quarterly revenue

3.29%

846.7M

Estimated quarterly net income

0.58%

148.42M

Market cap / expected revenue

29.21x

Revenue

Forecast

846.7M

Previous quarter

+0.21%

Net income

Forecast

148.42M

Previous quarter

+6.93%

Revenue and Net Income Trend

RevenueNet income

Quarterly Performance

13 quarters

Financial Statements

SEC Filings

12 filings shown

Open the original SEC filings to view the full document.

FormFiling DateReport DateAccessionLink
8-KJun 1, 2026May 31, 20260000105770-26-000080Document
8-K/AMay 20, 2026May 7, 20260000105770-26-000077Document
4May 14, 2026May 12, 20260000105770-26-000075Document
SDMay 13, 2026No data0000105770-26-000074Document
8-KMay 11, 2026May 7, 20260000105770-26-000068Document
144May 7, 2026No data0001959173-26-003387Document
4May 6, 2026May 4, 20260000105770-26-000066Document
4May 6, 2026May 4, 20260000105770-26-000065Document
4May 6, 2026May 4, 20260000105770-26-000064Document
4May 6, 2026May 4, 20260000105770-26-000063Document
4May 6, 2026May 4, 20260000105770-26-000062Document
4May 6, 2026May 4, 20260000105770-26-000061Document

Latest News

12 articles
ZacksJun 25, 2026, 12:00 AMnasdaq

AMN Expands Workforce Intelligence Through Brightfield Alliance

AMN Healthcare's alliance with Brightfield boosts workforce intelligence, pairing TDX with analytics to support smarter healthcare labor planning.

Open article
ZacksJun 24, 2026, 12:00 AMnasdaq

MiniMed Launches Abbott's Instinct Sensors Across European Markets

MMED expands its European diabetes tech reach with Abbott sensor integration, boosting user flexibility and its connected care ecosystem.

Open article
ZacksJun 23, 2026, 12:00 AMnasdaq

Revvity Launches Signals AI to Advance Scientific R&D Workflows

RVTY expands AI capabilities in Signals software with Signals AI, designed to help scientists turn connected R&D data into actionable insights.

Open article
ZacksJun 22, 2026, 12:00 AMnasdaq

INSP Highlights New OSA Data and PREDICTOR Study at SLEEP 2026

Inspire Medical's SLEEP 2026 updates spotlight new Inspire V data, remote patient tools and research supporting wider OSA therapy adoption.

Open article
ZacksJun 19, 2026, 12:00 AMnasdaq

10x Genomics, Cleveland Clinic Team Up on Bladder Cancer Diagnostics

TXG collaborates with the Cleveland Clinic to advance bladder cancer diagnostics using Flex Apex, Xenium and potentially Atera.

Open article
ZacksJun 19, 2026, 12:00 AMnasdaq

Baxter's Unit Synovis MCA to Lead Global Rollout of the SHIYA Platform

BAX gains as Synovis MCA signs a multi-year deal to commercialize MediThinQ's SHIYA 3D surgical visualization platform worldwide.

Open article
ZacksJun 19, 2026, 12:00 AMnasdaq

CAH Stock Up Nearly 8% YTD: Will the Uptrend Continue in the Rest of 2026?

Cardinal Health has gained nearly 8% in 2026 as specialty pharma growth, rising EPS, and expanding healthcare services fuel investor optimism.

Open article
ZacksJun 18, 2026, 12:00 AMnasdaq

COR Stock Down Nearly 18% YTD: Should You Buy, Hold or Sell?

COR shares are down 18% YTD, but rising EPS guidance, specialty pharma growth and strategic expansion could make this pullback worth watching.

Open article
ZacksJun 18, 2026, 12:00 AMnasdaq

Cencora Launches Enhanced Nucleus Solution for Specialty Practices

COR's enhanced Nucleus platform targets complex specialty medication workflows, with a pilot underway across more than 20 physician practice sites.

Open article
ZacksJun 18, 2026, 12:00 AMnasdaq

ANGO Gains FDA IDE Approval for NanoKnife BPH Feasibility Study

AngioDynamics' FDA IDE approval for RELIEF advances NanoKnife IRE study as a potential minimally invasive BPH treatment.

Open article
ZacksJun 17, 2026, 12:00 AMnasdaq

LivaNova Reports Improved OSA Outcomes With PolySync Programming

LIVN's PolySync data show an 84.5% AHI response rate in OSA patients, building on OSPREY results for its aura6000 System.

Open article
ZacksJun 16, 2026, 12:00 AMnasdaq

InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR

NSPR's positive CGUARDIANS II data show 100% acute device success, supporting a potential FDA approval for CGuard Prime TCAR in late 2026.

Open article